Leena Helle
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Research top 10%
- Breast Cancer Treatment Studies
Papers in
- Oncology 9
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 3
- Lung Cancer Research Studies 2
-
- Breast Cancer Treatment Studies 4
- Co-authors
- Petri Bono (3 shared papers)Vesa Kataja (3 shared papers)Päivi Auvinen (3 shared papers)Heikki Joensuu (3 shared papers)Pirkko‐Liisa Kellokumpu‐Lehtinen (3 shared papers)R. Kokko (3 shared papers)Mika Leinonen (3 shared papers)R. Asola (2 shared papers)
In The Last Decade
Leena Helle
10 papers receiving 497 citations
Peers
Comparison fields: 5 of 51
- Oncology 457
- Cancer Research 248
- Radiology, Nuclear Medicine and Imaging 155
- Pulmonary and Respiratory Medicine 84
- Cardiology and Cardiovascular Medicine 56
Countries citing papers authored by Leena Helle
This map shows the geographic impact of Leena Helle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leena Helle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leena Helle more than expected).
Fields of papers citing papers by Leena Helle
This network shows the impact of papers produced by Leena Helle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leena Helle. The network helps show where Leena Helle may publish in the future.
Co-authors
The 25 scholars most cited alongside Leena Helle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 326 | |
| 2 | 2011 | 76 | |
| 3 | 1993 | 44 | |
| 4 | 1990 | 23 | |
| 5 | 2013 | 22 | |
| 6 | 1992 | 11 | |
| 7 | 1994 | 10 | |
| 8 | Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer. | 1997 | 5 |
| 9 | 1992 | 1 | |
| 10 | Combination of carmofur and interferon-alpha-2B in advanced gastrointestinal cancer--a phase II pilot study. | 1994 | 1 |
| 11 | 1996 | 1 |
About Leena Helle
Leena Helle is a scholar working on Oncology, Cancer Research, Genetics, Molecular Biology and Cardiology and Cardiovascular Medicine, having authored 11 papers that have together received 520 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), Breast Cancer Treatment Studies (4 papers), HER2/EGFR in Cancer Research (3 papers), Estrogen and related hormone effects (3 papers), Neuroendocrine Tumor Research Advances (2 papers), Cancer therapeutics and mechanisms (2 papers), Chemotherapy-induced cardiotoxicity and mitigation (2 papers) and Lung Cancer Research Studies (2 papers). The work is most often cited by research in Oncology (457 citations), Cancer Research (248 citations), Radiology, Nuclear Medicine and Imaging (155 citations), Pulmonary and Respiratory Medicine (84 citations) and Cardiology and Cardiovascular Medicine (56 citations). Leena Helle has collaborated with scholars based in Finland, Sweden and Latvia. Frequent co-authors include Petri Bono, Vesa Kataja, Päivi Auvinen, Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, R. Kokko, Mika Leinonen, R. Asola, Marjo Pajunen and Sirkku Jyrkkiö. Their work appears in journals such as Acta Oncologica, Journal of Clinical Oncology, Breast Cancer Research and Treatment, European Journal of Cancer and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.